Home » Clinical Trials »  Search Clinical Trials

Therapeutic Areas:  |  Hematology  |  Oncology

Search Medical Condition
Please enter condition
Please choose location

Chronic Lymphocytic Leukemia Clinical Trials

A listing of Chronic Lymphocytic Leukemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (372) clinical trials

A Study of E6201 for the Treatment of Advanced Hematologic Malignancies With FLT3 Mutation

Phase 1 (Safety Run-In): Following Screening, a total of up to 30 subjects in up to 5 dose cohorts will be enrolled to establish the RP2D. The safety run-in phase will be a standard 3+3 cohort design. Phase 2a (Expansion): Once the Phase 1 Safety Run-In portion of the study ...

Phase

Nivolumab With Ibrutinib for Relapsed Refractory or High-Risk Untreated Patients With Chronic Lymphocytic Leukemia (CLL)

Study Groups and Study Drug Administration: If you are found to be eligible to take part in this study, you will be assigned to 1 of 2 study groups, depending on if you are already taking ibrutinib or not. If you are NOT already taking ibrutinib, you will be assigned ...

Phase

Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma

This is a Phase I, first in human clinical study with ADCT-301 to evaluate the safety and tolerability and pharmacokinetics of ADCT-301 in patients with relapsed/refractory lymphoma. ADCT-301 is a human monoclonal antibody attached via a cleavable linker to a pyrrolobenzodiazepine (PBD) warhead which, when internalized by antigen expressing cells, ...

Phase

iCare for Cancer Patients

As part of normal clinical care, subjects will undergo peripheral blood draws and biopsies for disease assessment of their cancer. In cases of hematological malignancies, bone marrow aspiration & biopsy are routinely performed. As part of this project, the following will be done to the samples collected and with clinical ...

Phase N/A

A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors

The study will be conducted in two parts. Part A is a dose escalation study to determine a safe and tolerable dose of ASN002 for subjects with relapsed or refractory lymphoma, or advanced solid tumors. Part A will also characterize the pharmacokinetics and pharmacodynamics of ASN002 through blood sampling. Subjects ...

Phase

Study of Idarubicin Cytarabine and Nivolumab in Patients With High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)

Study Groups: If you are found to be eligible to take part in this study, you will be assigned to a study group based on when you join this study. Up to 3 groups of 3 - 6 participants will be enrolled in Phase 1 of the study, and up ...

Phase

Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.

This is phase 1 study for patients with CLL or small lymphocytic lymphoma (SLL) experiencing disease progression on single ibrutinib. This study will evaluate the optimal ibrutinib dose (including doses higher than 420 mg) when combined with obinutuzumab. During the screening period, patients will continue on ibrutinib at their previous ...

Phase

First-line Therapy With Ibrutinib Fludarabine Cyclophosphamide and Obinutuzumab (GA-101) (iFCG) for Patients With Chronic Lymphocytic Leukemia (CLL)

Study Drug Administration: Each study cycle is 4 weeks (28 days). If you are found to be eligible to take part in this study, you will receive the study drug combination on the following schedule during Cycles 1-3: You will receive obinutuzumab by vein over 4-6 hours on the following ...

Phase

Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem Cells and Allogeneic Transplantation in Patients With Advanced Hematological Malignancies

Current protocols use G-CSF to mobilize hematopoietic progenitor cells from matched sibling and volunteer unrelated donors. Unfortunately, this process requires four to six days of G-CSF injection and can be associated with side effects, most notably bone pain and rarely splenic rupture. BL-8040 is given as a single SC injection, ...

Phase

Study to Evaluate Safety and Preliminary Efficacy of MOR208 With Idelalisib or Venetoclax in R/R CLL/SLL Patients Pretreated With BTKi (COSMOS)

The purpose of this study is to evaluate the clinical safety and preliminary efficacy of MOR00208 combined with idelalisib or venetoclax. The study will include safety run-in phase for each cohort with an evaluation of the safety data by an Independent Data Monitoring Committee.

Phase